EXTRANEAL Drug Patent Profile

When do Extraneal patents expire, and what generic alternatives are available?

Extraneal is a drug marketed by Vantive Us Hlthcare and is included in one NDA.

The generic ingredient in EXTRANEAL is icodextrin. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the icodextrin profile page.

Summary for EXTRANEAL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	11
Drug Prices:	Drug price information for EXTRANEAL
What excipients (inactive ingredients) are in EXTRANEAL?	EXTRANEAL excipients list
DailyMed Link:	EXTRANEAL at DailyMed

See drug prices for EXTRANEAL

Recent Clinical Trials for EXTRANEAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital, Sun Yat-Sen University	Phase 4
Iperboreal Pharma Srl	Phase 3
Baxter Healthcare Corporation	N/A

See all EXTRANEAL clinical trials

Pharmacology for EXTRANEAL

Drug Class	Blood Coagulation Factor Calculi Dissolution Agent Osmotic Laxative Phosphate Binder
Mechanism of Action	Magnesium Ion Exchange Activity Osmotic Activity Phosphate Chelating Activity
Physiological Effect	Increased Coagulation Factor Activity Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Inhibition Small Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

US Patents and Regulatory Information for EXTRANEAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002		RX	Yes	Yes

Expired US Patents for EXTRANEAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002

International Patents for EXTRANEAL

See the table below for patents covering EXTRANEAL around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	211101	GLUCOSE POLYMER CONTAINING COMPOSITIONS FOR USE IN PERITONEAL DIALYSIS
Japan	S6248701	GLUCOSE POLYMER
Finland	862563

Market Dynamics and Financial Trajectory for EXTRANEAL (R promedio: 120 words)

Last updated: January 28, 2026

EXTRANEAL (dialysate solution containing glucose polymers) has established a niche within peritoneal dialysis treatments, particularly for acute and chronic renal failure management. The drug, developed by Baxter International, received U.S. FDA approval in 2000 and later expanded its global reach. The growing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), driven by increasing diabetes and hypertension cases, underpins heightened demand. Market competition primarily involves alternative solutions like traditional dextrose-based dialysates and newer biocompatible formulations. The global peritoneal dialysis market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.1% from 2022 to 2030, reaching USD 9.7 billion, with EXTRANEAL holding a significant but competitive position. Patent protections, regulatory approvals, and healthcare infrastructure influence commercial and R&D trajectories.

Market Landscape for EXTRANEAL

Element	Details
Original Manufacturer	Baxter International
FDA Approval Year	2000
Indications	Peritoneal dialysis for acute and chronic renal failure
Key Competitors	Physioneal, Extraneal (biosimilar and generic formulations), newer biocompatible solutions
Geographic Markets	North America, Europe, Asia-Pacific, Latin America
Market Share (Est.)	Estimated around 15-20% within peritoneal dialysis dialysate segment

Factors Driving Market Growth

1. Increasing CKD & ESRD Prevalence

• The World Health Organization (WHO) estimates 850 million people with CKD globally[1].
• Diabetes and hypertension are primary risk factors, both rising concurrently.
• ESRD cases are expected to grow at 5-7% annually, augmenting demand for dialysis solutions.

2. Aging Population

• Patients aged >65 are more susceptible to CKD, expanding market size.
• Aging populations prominent in North America, Europe, and Japan.

3. Technological and Formulation Innovations

• Development of biocompatible and less-cytotoxic dialysates to replace traditional dextrose solutions.
• EXTRANEAL utilized for its glucose polymer formulation, providing more stable osmotic agents.

4. Regulatory and Reimbursement Policies

• Favorable reimbursement regimes in developed countries promote adoption.
• Regulatory approvals continue expanding, notably in emerging markets.

5. Healthcare Infrastructure Expansion

• Growth of outpatient dialysis centers enhances accessibility.
• Increasing adoption of peritoneal dialysis at home, driven by COVID-19 pandemic.

Financial Trajectory Analysis

1. Revenue Trends and Valuations

While Baxter does not publish specific revenues for EXTRANEAL alone, estimates place its contribution in the dialysis segment at approximately USD 600-800 million annually[2].

Year	Estimated Revenue (USD millions)	Notes
2018	550	Stable growth from prior years
2019	620	Increased adoption in Asia-Pacific
2020	700	COVID-19 pandemic shifts focus to home-based dialysis
2021	750	Market expansion in emerging economies
2022	800	Continued growth, driven by aging demographics

2. R&D and Regulatory Insight

• Baxter invested approximately USD 400 million annually in R&D[3].
• Ongoing development of biocompatible variants aims to extend product lifecycle and compliance with new standards.
• Regulatory pathways in regions like China and India are accelerating, offering new revenue streams.

3. Pricing Dynamics

• Average wholesale price per liter varies from USD 10-15 depending on region.
• Reimbursement policies impact net revenue significantly.
• Patent protections in major markets secure pricing premium until 2025, post which biosimilars may enter.

4. Competitive and Market Risks

• Patent expirations threaten future exclusivity.
• Competition from biosimilars and alternative formulations pressures pricing.
• Emerging economies may adopt lower-cost generics, affecting margins.

Comparison of Market Segments & Product Positioning

Segment	Market Share (%)	Key Differentiators	Challenges
Traditional Dextrose Dialysate	~50	Cost-effective, widely used	Cytotoxicity, biocompatibility issues
Biocompatible Solutions	~30	Better tissue compatibility	Higher cost, regulatory hurdles
EXTRANEAL (Glycosylated Dialysate)	15-20	Osmotic stability, safety profile	Market penetration, patent dependence

Regulatory and Policy Environment

Region	Key Policies	Approval Status	Impact on EXTRANEAL
North America	CMS reimbursement, FDA regulations	Approved 2000, ongoing post-market surveillance	Stable, high adoption
Europe	EMA regulations, reimbursement schemes	Approved, covered under national health systems	Growing adoption
Asia-Pacific	Emerging markets, local approval pathways	Clinical trials ongoing, recent approvals in Japan, China	Expanding rapidly, price sensitivity
Latin America	Cost considerations, institutional approvals	Approvals vary, often delayed	Focus on cost-effective alternatives

Future Outlook: Key Drivers and Constraints

Driver	Impact	Status
Aging demographics	Increased demand for dialysis therapies	High
Innovation in biocompatible solutions	Product pipeline enriches future offerings	Moderate to high
Regulatory streamlining	Faster market access in emerging regions	Increasing
Patent cliffs and biosimilar competition	Margin pressures, necessitating innovation and differentiation	High
Healthcare infrastructure investment	Expanded access, particularly for home dialysis	Upward trend

---

Key Takeaways

• Market Growth: The global peritoneal dialysis market is projected to grow at a CAGR of 6.1% through 2030, driven by CKD prevalence, aging populations, and technological advancements.
• Revenue Trajectory: EXTRANEAL’s estimated revenues are around USD 600-800 million annually, supported by expansion in emerging markets and innovation efforts.
• Competitive Landscape: The segment features traditional dextrose solutions, biocompatible innovations, and biosimilars, with patent protections providing temporary exclusivity.
• Regulatory Influences: Regulatory approvals and reimbursement policies significantly impact market penetration and profitability.
• Risks & Opportunities: Patent expiries, biosimilar competition, and price pressures pose challenges, but innovation and expanding access in emerging economies create growth opportunities.

---

FAQs

1. What are the primary factors influencing EXTRANEAL’s market position?
Demand drivers include rising CKD/ESRD prevalence, technological innovations in biocompatibility, regulatory environments, and healthcare infrastructure expansion, especially for home-based dialysis.

2. How does patent protection affect EXTRANEAL’s market longevity?
Patents, typically valid until 2025, secure exclusive rights that enable premium pricing; post-expiry, biosimilar entries may reduce prices, impacting revenue.

3. What regional variations exist in the adoption of EXTRANEAL?
North America and Europe show high adoption rates due to established healthcare systems, while emerging markets are rapidly expanding but are more price-sensitive.

4. How do biosimilars influence EXTRANEAL’s future?
Biosimilar competitors could erode market share and margins once patents expire, emphasizing the need for innovation and market differentiation.

5. What are the key regulatory hurdles facing EXTRANEAL?
Regulatory approval in new markets, compliance with biocompatibility standards, and post-marketing surveillance requirements represent ongoing hurdles.

---

References

[1] WHO Global CKD Report, 2020
[2] Baxter International 10-K filings, 2022
[3] Industry R&D expenditure reports, 2022